ESMO I/O: Novel B7-H3 Targeting Dual Nanobody NK Cell Engagers Display Robust Activity Against a Broad Spectrum of Solid and Hematologic Malignancies.

December 8, 2021

GT Biopharma Management Update Conference Call Webcast – Replay

November 30, 2021

Dr. Jeff Miller ESMO Congress 2021 Presentation

September 17, 2021

Second Quarter Financial Results & Business Update (8/13/21 registration)

August 6, 2021

The Raymond James Human Health Innovation Conference June 2021- REPLAY

1-7-21 Investor Update

January 7, 2021

GTB-3550 TriKE™ - Target Directed Serial Killing of AML Cancer Cell by NK Cells

January 7, 2021

GTB-3550 ASH 2020 Meeting Supplement Presentation – Treatment of HR-MDS Patient

December 16, 2020

GTB-3550 Clinical Trial Interim Results: Erica Warlick, M.D., Principal Investigator. American Society of Hematology (ASH) meeting, December 5, 2020.

December 5, 2020

GT Biopharma Interview with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco